DARBID
LOE ApproachingNDAORALTABLET
Approved
Oct 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DARBID is an oral small-molecule tablet approved by GSK in 1957 for unknown indications. The mechanism of action and pharmacologic class are not publicly disclosed in available data. This is a legacy product with a long clinical history.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), suggesting defensive team focus on market retention and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate this product is not currently a hiring priority at GSK. Roles on this team are likely focused on defending market share and managing transition to generic competition rather than growth.
Brand ManagerField Sales Representative
Worked on DARBID at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.